Avalyn Pharma Inc

AVLNHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 2:24 PM ET

31.25+0.08 (0.26%)

2026-11-11 20:24 CET

Market cap

1,381.86 USD m

Revenue, TTM

0.00 USD m

Net income, TTM

-28.93 USD m

Free cash flow, TTM

-26.34 USD m

EPS diluted, TTM

-0.65

P/E

Compare

Price

AVLN against its 20 and 50-day averages

2050missearnings

22.2% under the 52-week high of 40.17 on 18 Aug 2026. 52-week low 22.24 on 20 Oct 2026. Last 15 sessions, 28.4% high to low

Profile

AVLN

52-week range, 50% of the way up

22.2440.17

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

Index	RUT
Employees	50
IPO	Apr 30, 2026
ATR, 14d	1.95
Rel volume	0.76
Short float	8.64%
Insider own	39.92%
Inst own	66.13%

Snapshot

6 groups

Valuation

Index	RUT
Market Cap	1.39B
Enterprise Value	1.05B
Income	-
Sales	-
Book/sh	8.99
Cash/sh	7.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	50
IPO	Apr 30, 2026

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.48
P/C	3.93
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	33.10
Current Ratio	33.10
Debt/Eq	0.04
LT Debt/Eq	0.04
Option/Short	Yes / Yes

Earnings

EPS (ttm)	-
EPS next Y	-2.96
EPS next Q	-0.71
EPS this Y	13.10%
EPS next Y	9.65%
EPS next 5Y	7.23%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-26.17% -

Ownership

Insider Own	39.92%
Insider Trans	0.00%
Inst Own	66.13%
Inst Trans	138.72%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	17.41%
SMA50	8.29%
SMA200	4.50%
Trades	-

Technical

Shs Outstand	44.33M
Shs Float	26.64M
Short Float	8.64%
Short Ratio	7.10
Short Interest	2.30M
52W High	40.17 -22.21%
52W Low	22.24 40.51%
Volatility	8.90% 7.85%
ATR (14)	1.95
RSI (14)	66.09
Beta	-
Rel Volume	0.76
Avg Volume	324.13K
Volume	187,522

Performance

Perf Week	13.76%
Perf Month	31.63%
Perf Quarter	-14.57%
Perf Half Y	1.36%
Perf YTD	20.19%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.20
Target Price	61.80
Prev Close	31.17
Price	31.25
Change %	0.26%

Analyst ratings

latest 5 of 5

Date	Action	Analyst	Rating change	Target	Implied
Oct 02, 2026	Initiated	RRaymond James	Outperform	$60	+92.0%
May 26, 2026	Initiated	MMorgan Stanley	Overweight	$53	+69.6%
May 26, 2026	Initiated	JJefferies	Buy	$52	+66.4%
May 26, 2026	Initiated	GGuggenheim	Buy	$80	+156.0%
May 26, 2026	Initiated	EEvercore ISI	Outperform	$51	+63.2%

Date

Action

Analyst

Rating change

Target

Implied

Oct 02, 2026

Initiated

RRaymond James

Outperform

$60

+92.0%

May 26, 2026

Initiated

MMorgan Stanley

Overweight

$53

+69.6%

May 26, 2026

Initiated

JJefferies

Buy

$52

+66.4%

May 26, 2026

Initiated

GGuggenheim

Buy

$80

+156.0%

May 26, 2026

Initiated

EEvercore ISI

Outperform

$51

+63.2%

Peers

Mkt cap

Ticker	Company	Mkt cap
CTNM	Contineum Therapeutics Inc	424.07M
MNKD	Mannkind Corp	1.35B
SVRA	Savara Inc	1.13B
INSM	Insmed Inc	26.21B
PLRX	Pliant Therapeutics Inc	48.20M
LQDA	Liquidia Corp	4.91B
TECX	Tectonic Therapeutic Inc	438.26M
UTHR	United Therapeutics Corp	25.42B
IVA	Inventiva ADR	946.69M
UPB	Upstream Bio Inc	179.11M

Ticker

Company

Mkt cap

CTNM

Contineum Therapeutics Inc

424.07M

MNKD

Mannkind Corp

1.35B

SVRA

Savara Inc

1.13B

INSM

Insmed Inc

26.21B

PLRX

Pliant Therapeutics Inc

48.20M

LQDA

Liquidia Corp

4.91B

TECX

Tectonic Therapeutic Inc

438.26M

UTHR

United Therapeutics Corp

25.42B

IVA

Inventiva ADR

946.69M

UPB

Upstream Bio Inc

179.11M

Insider trading

3 filings

Insider	Relationship	Date	Transaction	Cost	Shares	Value	Total held	Form
Novo Holdings A/S	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	3,883,289	May 05 04:15 PM
Carroll Jill	Director	May 01 '26	Buy	18.00	277,778	5,000,004	2,186,562	May 01 06:50 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	2,186,562	May 01 06:46 PM

Held by

AUM

Ticker	Company	AUM
VTI	Vanguard Morningstar Total Stock Market ETF	AUM: 687.42B
IWM	iShares Russell 2000 Index Fund	AUM: 77.38B
VXF	Vanguard Extended Market Index ETF	AUM: 30.47B
XPH	State Street SPDR S&P Pharmaceuticals ETF	AUM: 516.35M
IWO	iShares Russell 2000 Growth ETF	AUM: 14.06B
VTWO	Vanguard Russell 2000 Index ETF	AUM: 16.75B
SCHA	Schwab U.S. Small-Cap ETF	AUM: 22.25B
TMSL	T. Rowe Price Small-Mid Cap ETF	AUM: 3.28B
IHE	iShares U.S. Pharmaceuticals ETF	AUM: 1.72B
IWN	iShares Russell 2000 Value ETF	AUM: 14.10B

Ticker

Company

AUM

VTI

Vanguard Morningstar Total Stock Market ETF

AUM: 687.42B

IWM

iShares Russell 2000 Index Fund

AUM: 77.38B

VXF

Vanguard Extended Market Index ETF

AUM: 30.47B

XPH

State Street SPDR S&P Pharmaceuticals ETF

AUM: 516.35M

IWO

iShares Russell 2000 Growth ETF

AUM: 14.06B

VTWO

Vanguard Russell 2000 Index ETF

AUM: 16.75B

SCHA

Schwab U.S. Small-Cap ETF

AUM: 22.25B

TMSL

T. Rowe Price Small-Mid Cap ETF

AUM: 3.28B

IHE

iShares U.S. Pharmaceuticals ETF

AUM: 1.72B

IWN

iShares Russell 2000 Value ETF

AUM: 14.10B

Key figures

Revenue, TTM	0.00
Net income, TTM	-28.93
EPS diluted, TTM	-0.65
EBIT, TTM	-31.29
Free cash flow, TTM	-26.34
Gross margin	-%
Operating margin	-%
Net margin	-%
Market cap	1,381.86
P/E	-
Sales Y/Y, TTM	-

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Analysts
2026Q2	2026-08-12	-0.980	-0.777	-0.540	0.00	3
2026Q1	2026-06-03	-21.830	-5.977	-0.510	0.00	3
2026Q3	-	-	-0.713	-	-	3
2026Q4	-	-	-0.833	-	-	3

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
2025FY	-4.033	-	-3.770	0.00	-
2026FY	-	-3.276	-	-	0.00
2027FY	-	-2.960	-	-	0.00
2028FY	-	-3.010	-	-	0.00
2029FY	-	-3.487	-	-	0.00
2030FY	-	-3.597	-	-	0.00

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
2026Q3	S	2026-10-01	3	0	0	0.00	0.00	0.00
2026Q3	S	2026-08-12	2	0	0	0.00	0.00	0.00
2026Q3	S	2026-06-03	2	0	0	0.00	0.00	0.00
2026Q3	S	2026-05-22	2	0	0	0.00	0.00	0.00
2026Q3	S	2026-05-21	1	0	0	0.00	0.00	0.00
2026Q3	R	2026-10-26	1	0	0	-0.59	-0.59	-0.59
2026Q3	R	2026-08-12	1	0	1	-0.59	-0.59	-0.59
2026Q3	R	2026-08-11	1	0	1	-0.59	-0.59	-0.59
2026Q3	R	2026-06-04	1	0	1	-0.54	-0.54	-0.54
2026Q3	R	2026-06-03	1	0	0	-0.50	-0.50	-0.50
2026Q3	R	2026-05-21	1	0	0	-0.50	-0.50	-0.50
2026Q3	E	2026-10-26	3	0	0	-0.71	-0.79	-0.64
2026Q3	E	2026-08-12	3	0	3	-0.71	-0.79	-0.64
2026Q3	E	2026-08-11	3	1	1	-0.64	-0.71	-0.52

Estimate history

Period	2024	2025
EPS, annual	-1.122	-1.922
EPS, quarterly	-0.395	-0.455	-0.606	-0.653
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26
Sales, annual	0	0
Period	2024	2025
Sales, quarterly	0	0	0	0
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26
Shares, annual	44.333	44.333	44.333
Period	2024	2025	MRQ
Shares, quarterly	44.333	44.333	44.333	44.333
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Total Revenue	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.11	0.04	0.03
Gross Profit	-0.11	-0.04	-0.03
Selling, General and Administrative Excl. Other	31.18	91.25	55.69
Research and Development	24.73	76.61	45.76
Other Operating Expense	0.00	0.00	0.00
Operating Income	-31.29	-91.29	-55.72
Interest Expense	0.27	0.00	0.00
Unusual Expense	0.00	0.00	1.40
Net Income Before Taxes	-28.93	-85.20	-49.74
Income Taxes	0.00	0.00	0.00
Consolidated Net Income	-28.93	-85.20	-49.74
Net Income From Continuing Operations	-28.93	-85.20	-49.74
Net Income	-28.93	-85.20	-49.74
EPS (Recurring)	-0.65	-1.92	-1.10
EPS (Basic, Before Extraordinaries)	-0.65	-1.92	-1.12
EPS (Diluted)	-0.65	-1.92	-1.12
EBITDA	-31.18	-91.25	-55.69
Non-Operating Income (Expense)	2.63	6.09	7.38
Other After Tax Adjustments	0.00	0.00	0.00
Stock Option Compensation Expense	2.79	3.27	2.47
Shares Outstanding	44.33	44.33	44.33
Market Capitalization	1,381.86	1,381.86	-

Income statement, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Total Revenue	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.11	0.06	0.01	0.01
Gross Profit	-0.11	-0.06	-0.01	-0.01
Selling, General and Administrative Excl. Other	31.18	27.85	21.77	18.71
Research and Development	24.73	22.89	17.88	15.32
Other Operating Expense	0.00	0.00	0.00	0.00
Operating Income	-31.29	-27.91	-21.78	-18.72
Interest Expense	0.27	0.10	0.00	0.00
Unusual Expense	0.00	0.00	0.00	0.00
Net Income Before Taxes	-28.93	-26.87	-20.19	-17.50
Income Taxes	0.00	0.00	0.00	0.00
Consolidated Net Income	-28.93	-26.87	-20.19	-17.50
Net Income From Continuing Operations	-28.93	-26.87	-20.19	-17.50
Net Income	-28.93	-26.87	-20.19	-17.50
EPS (Recurring)	-0.65	-0.61	-0.46	-0.39
EPS (Basic, Before Extraordinaries)	-0.65	-0.61	-0.46	-0.39
EPS (Diluted)	-0.65	-0.61	-0.46	-0.39
EBITDA	-31.18	-27.85	-21.77	-18.71
Non-Operating Income (Expense)	2.63	1.14	1.59	1.21
Other After Tax Adjustments	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	2.79	1.19	1.13	0.54
Shares Outstanding	44.33	44.33	44.33	44.33
Market Capitalization	1,381.86	1,374.33	-	-

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY
Cash & Short Term Investments	138.36	110.63
Short Term Receivables	0.54	0.59
Inventories	0.00	0.00
Other Current Assets	4.66	3.17
Total Current Assets	143.56	114.39
Net Property, Plant & Equipment	2.32	0.09
Total Investments and Advances	0.00	7.49
Other Assets	3.00	2.55
Total Assets	148.88	124.52
Short Term Debt Incl. Current Port. of LT Debt	0.44	0.00
Accounts Payable	3.76	2.28
Other Current Liabilities	9.89	6.47
Total Current Liabilities	14.09	8.74
Long Term Debt	1.23	0.00
Provision for Risks Charges	0.00	0.00
Other Liabilities	0.00	0.00
Total Liabilities	15.32	8.74
Non-Equity Reserves	0.00	0.00
Preferred Stock - Carrying Value	372.22	290.30
Common Equity	-238.66	-174.52
Total Shareholders Equity	133.56	115.78
Accumulated Minority Interest	0.00	0.00
Total Equity	133.56	115.78
Total Liabilities & Stockholders Equity	148.88	124.52
Book Value Per Share	-5.38	-3.94
Tangible Book Value Per Share	-5.38	-3.94
Full-Time Employees	50	-
Price to Book Ratio	3.47	-
Return on Assets	-62.33	-
Return on Equity	-68.34	-
Return on Invested Capital	-63.21	-42.97
Quick Ratio	10.19	13.08
Current Ratio	10.19	13.08

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Net Income	-28.93	-85.20	-49.74
Depreciation	0.11	0.04	0.03
Other Funds (Non Cash)	2.74	1.07	-0.01
Funds from Operations	-26.09	-84.09	-49.73
Extraordinary Item	0.00	0.00	0.00
Changes in Working Capital	0.01	2.61	1.36
Cash from Operating Activities	-26.08	-81.48	-48.37
Capital Expenditures	-0.27	-0.34	-0.10
Net Assets From Acquisitions	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00
Purchase or Sale of Investments	-118.44	10.40	-91.38
Purchase of Investments	-134.83	-109.30	-131.38
Sale Or Maturity of Investments	16.39	119.70	40.00
Other Uses	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00
Cash from Investing Activities	-118.71	10.06	-91.47
Cash Dividends Paid	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00
Change in Capital Stock	316.88	99.79	0.09
Repurchase of Common Pref Stock	0.00	0.00	0.00
Sale of Common Pref Stock	316.88	99.79	0.09
Proceedsfrom Stock Options	316.88	99.77	0.04
Issuance or Reduction of Debt, Net	-0.21	0.00	0.00
Change in Long Term Debt	-0.21	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00
Reduction of Long Term Debt	-0.21	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00
Cash from Financing Activities	316.67	99.79	0.09
Net Change in Cash	171.89	28.36	-139.75
Free Cash Flow	-26.34	-81.83	-48.46
Deferred Taxes & Investment Tax Credit	-	0.00	0.00

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Cash & Short Term Investments	352.43	123.13	-	-
Short Term Receivables	1.67	0.25	-	-
Inventories	0.00	0.00	-	-
Other Current Assets	3.67	3.88	-	-
Total Current Assets	357.77	127.26	-	-
Net Property, Plant & Equipment	3.35	2.68	-	-
Total Investments and Advances	61.10	0.00	-	-
Other Assets	3.23	5.72	-	-
Total Assets	425.45	135.66	-	-
Short Term Debt Incl. Current Port. of LT Debt	0.82	0.51	-	-
Accounts Payable	2.65	3.15	-	-
Other Current Liabilities	7.34	8.13	-	-
Total Current Liabilities	10.81	11.79	-	-
Long Term Debt	16.29	15.90	-	-
Provision for Risks Charges	0.00	0.00	-	-
Other Liabilities	0.00	0.00	-	-
Total Liabilities	27.10	27.69	-	-
Non-Equity Reserves	0.00	0.00	-	-
Preferred Stock - Carrying Value	0.00	372.22	-	-
Common Equity	398.35	-264.25	-	-
Total Shareholders Equity	398.35	107.98	-	-
Accumulated Minority Interest	0.00	0.00	-	-
Total Equity	398.35	107.98	-	-
Total Liabilities & Stockholders Equity	425.45	135.66	-	-
Book Value Per Share	8.99	-5.96	-	-
Tangible Book Value Per Share	8.99	-5.96	-	-
Full-Time Employees	55	54	-	-
Price to Book Ratio	3.47	-5.20	-	-
Return on Invested Capital	-6.98	-21.69	-	-
Quick Ratio	33.10	10.80	-	-
Current Ratio	33.10	10.80	-	-

Cash flow, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Net Income	-28.93	-26.87	-20.19	-17.50
Depreciation	0.11	0.06	0.01	0.01
Other Funds (Non Cash)	2.74	1.07	0.66	-0.01
Funds from Operations	-26.09	-25.74	-19.52	-17.51
Extraordinary Item	0.00	0.00	0.00	0.00
Changes in Working Capital	0.01	-4.16	-1.17	-1.77
Cash from Operating Activities	-26.08	-29.89	-20.70	-19.27
Capital Expenditures	-0.27	-0.32	0.00	-0.01
Net Assets From Acquisitions	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	-118.44	55.34	-36.69	24.13
Purchase of Investments	-134.83	0.00	-64.19	-2.87
Sale Or Maturity of Investments	16.39	55.34	27.50	27.00
Other Uses	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00
Cash from Investing Activities	-118.71	55.02	-36.69	24.12
Cash Dividends Paid	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00
Change in Capital Stock	316.88	-0.14	89.88	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	316.88	-0.14	89.88	0.00
Proceedsfrom Stock Options	316.88	-0.16	89.88	0.00
Issuance or Reduction of Debt, Net	-0.21	15.00	0.00	0.00
Change in Long Term Debt	-0.21	15.00	0.00	0.00
Issuance of Long Term Debt	0.00	15.00	0.00	0.00
Reduction of Long Term Debt	-0.21	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00
Cash from Financing Activities	316.67	14.86	89.88	0.00
Net Change in Cash	171.89	39.99	32.50	4.84
Free Cash Flow	-26.34	-30.21	-20.70	-19.28

Revenue breakdown

Revenue split	-

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	8.64%	2.3M	26.6M	282.05K
2026-10-15	8.84%	2.4M	26.6M	244.92K
2026-09-30	9.45%	2.5M	26.6M	248.42K
2026-09-15	7.86%	2.1M	26.6M	312.32K
2026-08-31	7.25%	1.9M	26.6M	313.98K
2026-08-14	7.78%	2.1M	26.6M	332.46K
2026-07-31	7.60%	2.0M	26.6M	373.05K
2026-07-15	7.96%	2.2M	27.5M	527.00K
2026-06-30	8.17%	2.2M	26.5M	558.52K
2026-06-15	4.94%	1.3M	26.5M	511.63K
2026-05-29	3.26%	0.9M	27.5M	654.30K
2026-05-15	4.06%	0.6M	13.8M	933.07K

Option chain

expiry 2026-11-20

Type	Strike	Bid	Ask	Last	IV	Open int	Delta	Theta	Vega
call	17.50	12.00	16.00	10.30	5.505	1.00	0.956	-0.064	0.005
call	20.00	9.50	13.50	7.80	4.616	1.00	0.945	-0.061	0.005
call	22.50	7.00	11.00	0.00	3.781	0.00	0.931	-0.058	0.006
call	25.00	4.50	8.50	2.50	3.119	10.00	0.909	-0.053	0.008
call	30.00	1.75	2.25	2.15	0.874	62.00	0.640	-0.085	0.018
call	35.00	0.20	0.40	0.25	0.802	50.00	0.196	-0.061	0.013
call	40.00	0.00	0.25	0.00	1.702	0.00	0.226	-0.134	0.015
call	45.00	0.00	0.25	0.13	2.143	4.00	0.193	-0.154	0.014
call	50.00	0.00	0.25	0.00	2.509	0.00	0.173	-0.168	0.013
put	17.50	0.00	0.25	0.12	2.331	59.00	-0.044	-0.056	0.005
put	20.00	0.00	0.25	0.15	3.454	1.00	-0.143	-0.202	0.012
put	22.50	0.00	0.25	0.48	1.715	10.00	-0.080	-0.070	0.007
put	25.00	0.00	0.25	0.80	1.140	10.00	-0.089	-0.050	0.008
put	30.00	0.70	1.00	3.80	0.818	3.00	-0.347	-0.082	0.018
put	35.00	3.80	4.60	7.40	1.048	1.00	-0.793	-0.063	0.014
put	40.00	7.00	10.50	0.00	2.289	0.00	-0.899	-0.051	0.009
put	45.00	12.00	15.50	0.00	2.734	0.00	-0.919	-0.058	0.007
put	50.00	16.80	20.50	0.00	3.171	0.00	-0.930	-0.062	0.007

Latest SEC filings

Filed	Form	Description	Period	Link
2026-09-17	4	Statement of changes in beneficial ownership of securities	2026-09-15	SEC
2026-09-17	3	Initial statement of beneficial ownership of securities	2026-09-15	SEC
2026-09-16	8-K	Current report	2026-09-15	SEC
2026-08-14	SCHEDULE 13G			SEC
2026-08-12	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-06-30	SEC
2026-08-12	8-K	Current report	2026-08-12	SEC
2026-08-11	SCHEDULE 13G			SEC
2026-08-06	SCHEDULE 13G/A			SEC
2026-07-01	8-K	Current report	2026-06-29	SEC
2026-06-17	8-K	Current report	2026-06-17	SEC
2026-06-03	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-03-31	SEC
2026-06-03	8-K	Current report	2026-06-03	SEC
2026-05-08	SCHEDULE 13D			SEC
2026-05-08	SCHEDULE 13D			SEC
2026-05-07	SCHEDULE 13G			SEC
2026-05-05	4	Statement of changes in beneficial ownership of securities	2026-05-01	SEC
2026-05-05	4	Statement of changes in beneficial ownership of securities	2026-05-01	SEC
2026-05-05	SCHEDULE 13G			SEC
2026-05-04	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-05-01	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-05-01	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-05-01	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC
2026-05-01	4	Statement of changes in beneficial ownership of securities	2026-04-29	SEC

Insider activity by month

Month	Bought	Buys
2026-11	0	0
2026-10	0	0
2026-09	0	0
2026-08	0	0
2026-07	0	0
2026-06	0	0
2026-05	25.00M	3
2026-04	0	0
2026-03	0	0
2026-02	0	0
2026-01	0	0
2025-12	0	0
2025-11	0	0

Institutional holders

Manager	% owned
FMR LLC	13.95%
Novo Holdings A/S	8.76%
SR ONE CAPITAL MANAGEMENT, LP	7.46%
PERCEPTIVE ADVISORS LLC	6.03%
MONTANOVA CAPITAL, LLC	5.65%
NVP Associates, LLC	5.12%
WELLINGTON MANAGEMENT GROUP LLP	4.97%
PRICE T ROWE ASSOCIATES INC /MD/	3.91%
Catalio Capital Management, LP	3.78%
T. Rowe Price Investment Management, Inc.	3.62%

Funds

Fund	% owned
Fidelity Small Cap Growth Fund	2.78%
Fidelity Small Cap Growth K6 Fund	1.41%
VANGUARD TOTAL STOCK MARKET INDEX FUND	1.21%
Global Bond Fund	0.98%
T. Rowe Price Small-Cap Stock Fund, Inc.	0.94%
T. Rowe Price Health Sciences Fund, Inc.	0.89%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund	0.87%
T. Rowe Price Small-Cap Value Fund, Inc.	0.77%
iShares Russell 2000 ETF	0.75%
T. Rowe Price New Horizons Fund, Inc.	0.75%

OakChart. AVLN. Cached 15 minutes.

Some panels did not load: news.